10.1071/HC24050
Journal of Primary Health Care

Supplementary Material

Contribution of the community pharmacist workforce to primary care through the lens of medicines classification: comparison of Aotearoa New Zealand and Australia

Chloë Campbell[A,*], *Caroline Morris*[A], *Bruce Sunderland*[B], *Lynn McBain*[A] and *Petra Czarniak*[B]

[A]Department of Primary Health Care and General Practice, University of Otago, Wellington 6242, New Zealand, Aotearoa

[B]Curtin Medical School, Faculty of Health Sciences, Curtin University, Perth, WA 6102, Australia

*Correspondence to: Email: chloe.campell@otago.ac.nz

Supplementary File S1: Table of medicines available for non-prescription pharmacist only supply in New Zealand and Australia

This table shows medicines classified as pharmacist-only in New Zealand and Australia as of 1 February 2024. The classification statement shown is pharmacist-only unless otherwise stated. Where in one country, the medicine was available via pharmacist-only classification, the corresponding classification from the other country is presented whether it be pharmacy-only, general sales or prescription medicine. The classification statements for Australia are extracted from the Poisons Standard and the classification statements for New Zealand from the Medicines Regulations 1984 Schedule 1 (Prescription, restricted, and pharmacy-only medicines) and individual Gazette notices where appropriate (referenced within table).

Australian Schedules: Schedule 2 = Pharmacy only; Schedule 3 = Pharmacist only, Schedule 4 = Prescription only

Generic Medicine Name	New Zealand Classification Statement	Australian Classification Statement
Adapalene	**Prescription medicine except when** in medicines containing 1 mg or less per millilitre or gram and when supplied by a pharmacist in a pack containing not more than 30 grams for the treatment of comedo, papular and pustular acne (acne vulgaris) of the face, chest or back.	In topical preparations containing 0.1 % or less for the treatment of acne vulgaris in adults and children over 12 years of age.
Adrenaline	In medicines containing 1% or less and more than 0.02% Adrenaline.	In preparations containing 1 % or less except those containing 0.02 % or less unless for injection.
Alclometasone	For dermal use in medicines containing 0.05% or less and in packs containing not more than 30g that have received the consent of the Minister or the Director-General to their distribution as restricted medicines and are sold in the manufacturer's original pack.	As the only therapeutically active substance in preparations for dermal use containing 0.05 % or less in packs containing 30 g or less.
Alimemazine (INN) Trimeprazine (BAN)	For oral use in adults & children over 2 years of age. For oral use for the treatment of insomnia when sold in the manufacturer's original pack containing not more than 10 dosage units.	In solid oral preparations except when in Schedule 2 or in liquid preparations containing 10 mg or less per 5 mL except in preparations for the treatment of children under 2 years of age.
Aminophylline	For oral use in liquid form in medicines containing 2% or less.	In liquid oral preparations containing 2 % or less.
Amyl nitrite	**Prescription medicine except when** sold to a person who holds a controlled substances licence (issued under section 95B of the Hazardous Substances and New Organisms Act 1996) authorising the person to possess cyanide. **Prescription medicine except when** sold to an exempt laboratory covered by a Hazardous Substances and New Organisms Act 1996 approved code of practice.	When in preparations for human therapeutic use and packaged in containers with child-resistant closures.

Aspirin	In slow-release forms; in enteric coated forms containing more than 300 milligrams per dose form.	**Pharmacy only Schedule 2**
Astodrimer sodium	Not classified in New Zealand.	Except in a condom lubricant.
Azatadine	For oral use in adults and children over 2 years of age.	In oral preparations
Bilastine	**Pharmacy only** For oral use.	In divided oral preparations containing 20 mg or less for the treatment of adults and adolescents 12 years of age and older.
Brompheniramine	For oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia. For oral use for the treatment of insomnia when sold in the manufacturer's original pack containing not more than 10 dosage units.	In oral preparations except when in Schedule 2, or for the treatment of children under 2 years of age.
Buciclizine	For oral use.	In oral preparations.
Butoconazole	For vaginal use.	In preparations for vaginal use.
Calcipotriol	**Prescription medicine except when** in medicines containing not more than 50 micrograms per gram or per millilitre and when sold in a pack of not more than 30g or 30 mL by a pharmacist to an adult with mild to moderate psoriasis previously diagnosed by a doctor.	**Prescription only - Schedule 4**
Cannabidiol	When supplied, in medicines with dosing instructions for 150 milligrams or less per day and containing not more than 4.5 grams, when sold in the manufacturer's original pack that has received consent from the Minister or Director-General, for adults aged 18 years and over, by a registered pharmacist.	In oral, oromucosal and sublingual preparations included in the Australian Register of Therapeutic Goods when: (a) The cannabidiol is either plant derived, or, when synthetic, only contains the (-) -CBD enantiomer, and (b) Comprises 98 % or more of the total cannabinoid content of the preparation plus several other requirements.
Celecoxib	**Prescription medicine**	In tablets or capsules each containing 200 mg or less in a primary pack of not more than 10 dosage units for the short-term treatment of acute pain due to primary dysmenorrhea or musculoskeletal or soft tissue injuries in adults.
Chloramphenicol	For ophthalmic use.	For ophthalmic use only.
Chlorbutanol (Chlorbutol)	In medicines containing more than 5%. **Pharmacy only** in medicines containing 5% or less and more than 0.5%	In preparations for human use except when in Schedule 2 or in preparations containing less than 0.5 %.

Chlorpheniramine	For oral use adults & children over 2 years of age other than in medicines used for the treatment of insomnia. For oral use for the treatment of insomnia when sold in the manufacturer's original pack containing not more than 10 dosage units.	Except when in Schedule 2; or for the treatment of children under 2 years of age.
Ciclopirox	For external use in medicines containing more than 2%; in preparations for application to the nails containing more than 8%.	In preparations for dermal use and for application to the nails except when in Schedule 2 or in preparations for the treatment of tinea pedis.
Cimetidine	In medicines for the symptomatic relief of heartburn, dyspepsia and hyperacidity or to be used on the recommendation of a registered medical practitioner that are sold in the manufacturer's original pack containing not more than 14 days' supply.	In a primary pack containing not more than 14 days supply.
Clemastine	For oral use.	In preparations for oral use.
Clobetasone	For dermal use in medicines containing 0.05% or less and in packs containing not more than 30g that have received the consent of the Minister or the Director-General to their distribution as restricted medicines and that are sold in the manufacturer's original pack.	(clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05 % or less, in packs of 30 g or less of the preparation.
Clotrimazole	For vaginal use.	In preparations for vaginal use.
Cyclizine	For oral use for nausea & vomiting - manufacturer's original pack containing not more than 6 tablets. For oral use for insomnia - manufacturer's original pack containing not more than 10 tablets.	In divided preparations for oral use in primary packs containing 6 dosage units or less.
Cyproheptadine	For oral use.	In oral preparations.
Dexchlorpheniramine	For oral use in adults & children over 2 years of age. For oral use in adults & children over 2 years of age treatment of insomnia in manufacturer's original pack containing not more than 10 tablets.	In oral preparations except when in Schedule 2, or for the treatment of children under 2 years of age.
Dextromethorphan	In liquid form when in packs containing not more than 600 mg and with a recommended daily dose of not more than 120 mg; in medicines for the treatment of symptoms of cough and cold in adults and children aged 6 years and over (otherwise **Prescription Medicine**).	**Pharmacy only Schedule 2**
Diclofenac	In solid dose form when containing 25 mg or less but more than 12.5 mg per dose form. Pack containing not more than 30 tablets or capsules.	In divided preparations for oral use containing 25 mg or less a pack containing 30 or less dosage unites, except where included in Schedule 2.

Dihydrocodeine	**Prescription medicine** **Controlled Drug Class C2**	When indicated for cough suppression and compounded with one or more other therapeutically active substances: in divided preparations containing 10mg or less per dosage unit and a recommended dose not exceeding 15 mg; or in undivided preparations containing 0.25 % or less with a recommended dose not exceeding 15 mg.
Diiodohydroxyquinoline (Iodoquinol)	For vaginal use	For vaginal use.
Dimenhydrinate	For oral use in medicines for adults and children over 2 years of age except when specified elsewhere in this schedule.	In oral preparations except when in Schedule 2.
Dimethindene	For oral use.	In oral preparations.
Diphenhydramine	For oral use in adults & children over 2 years of age other than in medicines used for the treatment of insomnia. For oral use for the treatment of insomnia when sold in the manufacturers original pack containing not more than 10 dosage units.	In oral preparations except when in Schedule 2 or for the treatment of children under 2 years of age.
Diphenoxylate	**Pharmacy only** In liquid form containing in each millilitre not more than 0.5 mg of diphenoxylate calculated as base and not less than 5 micrograms of atropine sulphate. In solid dose form containing not more than 2.5 mg of diphenoxylate calculated as base and not less than 5 micrograms of atropine sulphate.	In packs of 8 or less dosage units each containing 2.5 mg or less and a quantity of atropine sulfate equivalent to at least 1 % of the dose of diphenoxylate.
Dithranol	Listed without limitation.	For therapeutic use.
Doxylamine	For oral use in adults & children over 2 years of age other than in medicines used for the treatment of insomnia. For oral use for the treatment of insomnia when sold in the manufacturers original pack containing not more than 10 dosage units.	In oral preparations except when included in Schedule 2 or for the treatment of children under 2 years of age.
Econazole	For vaginal use.	In preparations for vaginal use.
Eletriptan	**Prescription medicine**	For oral use in tablets containing 40 mg or less per tablet and when in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms.
Erythrityl tetranitrate	Listed without limitation.	For therapeutic use.
Famciclovir	For the treatment of recurrent herpes labialis forms for oral use containing 500 mg or less I manufacturer's original pack containing up to 3 dosage units.	For oral use, in divided preparations containing a total dose of 1500 mg or less, for the treatment of herpes labialis (cold sores).

Flavoxate	Listed without limitation.	Listed without limitation.
Fluconazole	For treatment of vaginal candidiasis in medicines that have received the consent of the Minister or Director-General to their distribution as restricted medicines and that are sold in the manufacturer's original pack containing not more than 150 mg as a single dose.	In single-dose oral preparations containing 150 mg or less for the treatment of vaginal candidiasis.
Fluorides	For external use in liquid and non-liquid form. Except when supplied to a dental professional registered with the Dental Council. In liquid form in medicines containing 5.5g or less and more than 1 gram per litre or per kg and when sold in packs approved by the Minister or the Director-General for distribution as restricted medicines. In non-liquid form in medicines containing 5.5g or less and more than 1 gram per litre or per kg, except in medicines containing 1.5g or less and more than 1 gram per litre or per kg.	In liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child resistant closure except when included or expressly excluded from Schedule 2. In non-liquid preparations containing 5500 mg/kg or less of fluoride ion except: In preparations for therapeutic use containing 1500 mg/kg or less and more than 1000 mg/kg of fluoride ion compliant with the requirements of the Required Advisory Statements for Medicine Labels. In preparations for non-therapeutic use containing 1500 mg/kg or less and more than 1000 mg/kg fluoride ion, labelled with warnings "Do Not Swallow" and "Do Not Use in children six years or less" OR in preparations for supply to registered dental professionals or by approval of an appropriate authority.
Glucagon	Medicines containing 100 mcg or less per litre or kg.	Listed without limitation.
Glyceryl trinitrate	For oral, sublingual or rectal use.	In preparations for oral or rectal use.
Glycopyrronium	**Prescription medicine**	Except when included in Schedule 4.
Guaifenesin	For oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams when sold in the manufacturer's original pack containing more than 10 days' supply but not more than 30 days' supply. Except for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams when sold in the manufacturer's original pack containing not more than 10 days' supply. Except for oral use in medicines containing 2% or less or 200 milligrams or less per dose form.	**Pharmacy only Schedule 2**

Hydrocortisone and Hydrocortisone acetate	For dermal use in medicines containing 1% or less and more than 0.5% by weight of hydrocortisone base with no other active ingredient except an antifungal and in a quantity of 30 grams or less or 30 millilitres or less per container. For dermal use in medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base with no other active ingredient except 5% or less by weight of aciclovir and in a quantity of 2 grams or less or 2 millilitres or less per container in adults and children 12 years of age and older. In rectal medicines containing 1% or less but more than 0.5% by weight of hydrocortisone base and in combination with a local anaesthetic and in a quantity of 35 grams or less per container or up to 12 suppositories per pack.	In preparations for human therapeutic use containing 1% or less of hydrocortisone: For dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or For dermal use, in packs containing 2 g or less of such preparations, containing no other therapeutically active constituent other than aciclovir (5% w/w or less) in adults and adolescents (12 years of age and older); or For rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents: in undivided preparations, in packs of 35 g or less; or in packs containing 12 or less suppositories; except when included in Schedule 2.
Hyoscine butylbromide	For oral use in medicines containing not more than 20 mg per dose form and in packs containing not more than 10 tablets or capsules for the relief of muscle spasm of the gastrointestinal tract.	In undivided preparations for oral use with a recommended single dose not exceeding 20 mg in a pack containing 100mg or less when labelled for adults or children 6 years and over.
Ibuprofen	For oral use in tablets or capsules containing up to 400 mg per dose form in packs containing not more than 50 dose units that have received the consent of the Minister or Director-General to their distribution as restricted medicines and that are sold in the manufacturer's original pack labelled for use by adults and children over 12 years of age. For oral use in powder form containing 300 milligrams per dose with a recommended daily dose of not more than 1.2 grams and sold in the manufacturers original packs containing not more than 12 dose units and labelled for use in adults and children over 12 years of age.	In divided preparations each containing 400 mg or less in a primary pack containing not more than 50 dosage units, when labelled with a daily dose of 1200 mg or less of ibuprofen and not for children under 12 years of age. In modified release form each containing 600 mg in a primary pack containing not more than 32 units and labelled as above. Except when included or expressly excluded from Schedule 2.
Inositol nicotinate	Listed without limitation.	Listed without limitation.
Isoconazole	For vaginal use.	In preparations for vaginal use.
Isosorbide dinitrate	**Prescription medicine**	In oral preparations containing 10 mg or less per dosage unit.
Ketoprofen	In solid dose form containing 25 milligrams or less per dose form in packs of not more than 30 capsules or tablets.	In divided oral preparations containing 25 mg or less per dosage unit in a pack containing 30 dosage units or less.

Lansoprazole	For the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over or the relief of heartburn when sold in the manufacturer's original pack. Dosage forms for oral use containing 15 mg or less with a maximum daily dose of 15 mg containing not more than 14 dosage units.	In oral preparations containing 15 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply. Except when included in Schedule 2 (= 7 days' supply).
Levonorgestrel	For use as emergency post coital contraception in packs containing not more than 1.5 mg.	For emergency post-coital contraception.
Macrogols (polyethyleneglycols)	In oral preparations for bowel cleansing prior to diagnostic, medical or surgical procedures.	In preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.
Magnesium sulfate	**General sale**	For human therapeutic use in divided oral preparations except when containing 1.5 g or less per recommended daily dose.
Malathion	For external use in medicines containing more than 2%.	In preparations for human therapeutic external use except in preparations containing 2 % or less.
Mannityl hexanitrate	Listed without limitation.	For therapeutic use.
Meclozine	In a pack size of up to 10 dosage units for the treatment of insomnia. **Pharmacy Only:** In a sealed container of not more than 12 tablets or capsules for the prevention or treatment of travel sickness.	No Pharmacist only Schedule 3 entry. **Pharmacy only Schedule 2**: For motion sickness.
Melatonin	**Prescription except when** supplied in medicines for oral use containing 3 mg or less per immediate release dose unit, or 2 mg or less per modified release dose unit, when sold in the manufacturers original pack that has received consent from the Minister of Health or the Director General for the treatment of primary insomnia for adults aged 55 years or older for up to 13 weeks by a registered pharmacist.	In modified release tablets containing 2 mg or less of melatonin for monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep for adults aged 55 or over, in packs containing not more than 30 tablets. Immediate release preparations containing 5 mg or less for the treatment of jet lag in adults 18 years or over in a primary pack containing no more than 10 dosage units.
Mepyramine	For oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia. For oral use for the treatment of insomnia when sold in the manufacturer's original pack containing not more than 10 dosage units.	In oral preparations.
Methdilazine	For oral use.	In oral preparations.
Methenamine hippurate	Listed without limitation.	Not scheduled.

Metoclopramide	Only when compounded with paracetamol for the treatment of nausea associated with migraine. In packs of not more than 10 tablets or capsules.	When combined with paracetamol in packs not containing more than 10 dosage units in divided preparations labelled for the treatment of nausea associated with migraine.
Miconazole	For the treatment of oral candidiasis. For vaginal use.	For human topical use in preparations for the treatment of oral candidiasis, or for vaginal use.
Molnupiravir	For use in the treatment of COVID-19.	**Prescription only Schedule 4**
Mometasone	**Pharmacy only** For the treatment or prophylaxis of allergic rhinitis in adults and children over 12 years of age in aqueous nasal sprays delivering up to 50 micrograms per actuation when the maximum recommended daily dose is no greater than 200 micrograms (as a single dose) in a pack containing 200 actuations or less.	As the only therapeutically active substance in preparations for dermal use containing 0.1 % or less in packs containing 15 g or less. Aqueous nasal sprays are in Schedule 2.
Naloxone	**Prescription except when** except when supplied as ampoules with needles and syringes, or as a prefilled syringe, by those enabled to do so under the Health (Needles and Syringes) Regulations 1998 for the treatment of opioid overdose, and when supplied with instructions for use. **Prescription except when** provided as part of an approved emergency kit for the treatment of opioid overdose;	When used for treatment of opioid overdose.
Naproxen	**Pharmacy only** In solid dose form containing 250 mg or less per dose form in packs of not more than 30 tablets or capsules.	In a modified release dosage form of 600 mg or less in packs of 16 or less when labelled not for treatment of children under 12 years of age.
Nicotinic acid	(Listed as nicotinic acid except nicotinamide) In medicines containing 250 mg or less but more than 100 mg per dose form.	For human therapeutic use in divided preparations containing 250 mg or less except in preparations containing 100 mg or less or nicotinamide.
Nicotinyl alcohol	In medicines containing more than 100 mg per dose form.	Except in preparations containing 100 mg or less per dosage unit.
Nirmatrelvir	For use in the treatment of COVID-19.	**Prescription only Schedule 4**
Nitrofurantoin	**Prescription medicine except when** supplied for oral use containing 100 mg per dose unit when sold in a pack of 10 solid dosage units to a woman aged 16-65 years for the first-line empiric treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the Pharmaceutical Society of New Zealand training in the treatment of urinary tract infections.	**Prescription only Schedule 4**
Nystatin	For buccal use in the treatment of oral candidiasis. For vaginal use.	For topical use except when included in Schedule 2.

Omeprazole	**Pharmacy only** In divided solid dosage forms for oral use containing 20 mg or less with a maximum daily dose of 20 mg for the short-term symptomatic relief of gastric reflux-like symptoms in sufferers aged 18 years and over when sold in the manufacturer's original pack containing not more than 28 dosage units	In oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing no more than 14 days' supply, except when included in Schedule 2 (= 7 days' supply).
Orlistat	In medicines for weight control containing 120 mg or less per dose form.	In preparations for weight control containing 120 mg or less per dosage unit.
Oseltamivir	For the treatment or prophylaxis of influenza in adults and children aged 13 years and older who have been exposed to the influenza virus in solid dosage forms for oral use containing 75 mg in a pack size of up to 10 dosage units.	**Prescription only Schedule 4**
Oxiconazole	For vaginal use.	In preparations for vaginal use.
Pantoprazole	**Pharmacy only** In tablets or capsules containing 20 mg or less with a maximum daily dose of 20 mg for the short-term symptomatic relief of gastric reflux-like symptoms in patients aged 18 years or older. When sold in a manufacturer's original pack of not more than 28 dose units.	In oral preparations containing 20 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesphoageal reflux disease, in packs containing not more than 14 days' supply, except when included in Schedule 2 (= 7 days' supply).
Paracetamol	In modified-release forms containing 665 mg or less.	In liquid preparations for oral use except when in Schedule 2. When combined with ibuprofen in a primary pack containing 30 dosage units or less, except when included in Schedule 2. In modified release tablets or capsules containing 665 mg or less in a primary pack of 100 or less.
Pheniramine	For oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of insomnia. For oral use for the treatment of insomnia when sold in the manufacturer's original pack containing not more than 10 dosage units	In oral preparations except when in Schedule 2 or for children under 2 years of age.
Podophyllotoxin	For treatment of warts other than anogenital. In medicines containing 1% or less and more than 0.5%; **except** in medicines containing 1 mg or less of podophyllin per litre or per kilogram.	In preparations containing 1 % or less for human use for the treatment of warts other than anogenital, except when included in Schedule 2.
Podophyllum Emodi	For external use for the treatment of warts other than anogenital warts in medicines containing 20% or less and more than 10% of podophyllin; except in medicines containing 1 mg or less of podophyllin per litre or per kilogram.	In preparations containing 20 % or less of podophylin for human use for the treatment of warts other than anogenital warts, except when included in Schedule 2.

Podophyllum Peltatum	As for Podophyllum Emodi.	As for Podophyllum Emodi.
Prochlorperazine	For treatment of nausea associated with migraine in packs containing not more than 10 tablets or capsules. **Prescription except when** sold for the treatment of nausea associated with emergency contraception by pharmacists or nurses accredited to sell levonorgestrel for emergency contraception.	In divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.
Promethazine	For oral use adults & children over 2 years of age other than in medicines used for the treatment of insomnia. For oral use for the treatment of insomnia when sold in the manufacturer's original pack containing not more than 10 dosage units.	In oral preparations except when included in Schedule 2 or in preparations for the treatment of children under 2 years of age.
Pseudoephedrine	**Prescription medicine** Class B Controlled Drug	In preparations other than for stimulant, appetite suppression or weight control purposes when supplied in liquid preparations containing 800 mg or less of the hydrochloride or other preparations containing 720 mg or less of the hydrochloride in a primary pack.
Rabeprazole	**Prescription medicine**	In preparations containing 10 mg or less per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply except when included in Schedule 2 (= 7 days' supply).
Ritonavir	For use in the treatment of COVID-19.	**Prescription only Schedule 4**
Rizatriptan	For oral use in medicines for the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms when sold in a pack containing not more than 2 wafer and each wafer containing 5 mg or less approved by the Minister or the Director-General.	When in divided oral preparations containing 5 mg or less per dosage unit and when sold in packs containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of migraine symptoms.
Salbutamol	**Prescription medicine**	As the only therapeutically active substance in metered aerosols delivering 100 mcg or less per metered dose or in dry powders for inhalation delivering 200 mcg or less per dose
Salicylic acid	Except in medicines for dermal use containing 40% or less.	In preparations for dermal use except in preparations containing 40% or less of salicylic acid.
Santonin	Listed without limitation.	Listed without limitation

Selected* Oral Contraceptives * COC with ≤ 35 micrograms of ethinylestradiol combined with levonorgestrel or norethisterone (patients aged 16 – 39 years) POP with levonorgestrel, norethisterone or desogrestrel alone (patients aged 16 – 52 years)	**Prescription except when** supplied for oral contraception to women who meet the clinical and eligibility criteria of the Pharmacy Council and The Pharmaceutical Society of New Zealand approved training programme on the oral contraception when sold in Medsafe approved manufacturer's original pack containing not more than six months' supply by a registered pharmacist who has successfully completed the approved training programme.	**Prescription only Schedule 4**
Sildenafil and its structural analogues	**Prescription except when** in medicines for oral use containing 100 mg or less per dose unit when sold in the manufacturer's original pack containing not more than 12 solid dosage units for the treatment of erectile dysfunction in males aged 35-70 years by a registered pharmacist who has successfully completed a training programme endorsed by the Pharmaceutical Society of New Zealand.	**Prescription only Schedule 4**
Sodium phosphate	In oral preparations for bowel cleansing prior to diagnostic, medical or surgical procedures.	In preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.
Sodium picosulfate	In oral preparations for bowel cleansing prior to diagnostic, medical or surgical procedures.	In preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.
Stramonium	For oral use in liquid form. In solid dose form in medicines containing more than 0.3 milligrams per dose or more than 1.2 milligrams per recommended daily dose.	Not scheduled.
Sulfacetamide	For ophthalmic use in medicines containing 10% or less.	In preparations for ophthalmic use containing 10 % or less.
Sumatriptan	For the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms when sold in manufacturer's original pack and containing not more than 2 tablets (of 50 mg or less per tablet) that has received the consent of the Minister or Director-General.	When in divided oral preparations containing 50 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well-established pattern of symptoms.
Terbutaline	**Prescription medicine**	As the only therapeutically active substance in metered aerosols delivering 250 mcg or less per metered dose or in dry powders for inhalation delivering 500 mcg or less per dose.

Theophylline	When in liquid form for oral use in medicines containing 2% of less.	In liquid oral preparations containing 2 % or less.
Tioconazole	For vaginal use.	In preparations for vaginal use.
Triamcinolone	For buccal use in medicines containing 0.1% or less triamcinolone acetonide in packs containing no more than 5g.	For buccal use in preparations containing 0.1 % or less in a pack of 5 g or less.
Trimethoprim	**Prescription except when** for oral use containing 300 mg or less per dose unit when sold in a pack of **3 solid dosage** units to a woman aged 16-65 years for the treatment of an uncomplicated urinary tract infection by a registered pharmacist who has successfully completed the New Zealand College of Pharmacists' training in the treatment of urinary tract infections.	**Prescription only Schedule 4**
Triprolidine	For oral use in adults & children over 2 years of age.	In oral preparations except when in Schedule 2 or for the treatment of children under 2 years of age.
Ulipristal	**Prescription medicine**	For emergency post-coital contraception
Vitamin D	**Prescription medicine** For internal use in medicines containing more than 25 micrograms per recommended daily dose except in parenteral nutrition replacement preparations.	For human internal; therapeutic use in preparations containing 175 mcg or less per recommended single weekly dose except in preparations containing 25 mcg or less per recommended daily dose.
Zolmitriptan	For the acute relief of migraine attacks with or without aura in patients who have a stable, well-established pattern of symptoms in a pre-filled nasal spray device delivering not more than 5 mg of zolmitriptan when sold in a manufacturer's original pack of not more than 2 devices approved by the Minister or Director-General for distribution as a restricted medicine.	When in divided oral preparations containing 2.5 mg or less per dosage unit and when sold in a pack containing no more than 2 dosage units for the acute relief of migraine in patients who have a stable, well controlled pattern of symptoms.

Key to shading: Green = less restricted; Red = more restricted.

Supplementary File S2: Pilots/trials in New Zealand and Australia

This table provides further detail of the pilots/trial in New Zealand and Australia mentioned in the article.

Pilot	Description
New Zealand Minor Ailments Service Pilot – Winter 2023 [1]	As part of the Winter Preparedness Plan to reduce pressure on the health system, Te Whatu Ora – Health New Zealand funded the Minor Health Conditions Service through community pharmacies in particular areas. This provided advice and, if needed, free medicines or referral for further support for some groups of people, for a range of minor health conditions. Funding for this service ran from 12 June 2023 until 30 September 2023. Conditions included in the pilot were: - Acute diarrhoea, vomiting, dehydration - Bacterial eye infection - Eye inflammation - Pain/fever - Scabies - Headlice - Eczema/dermatitis - Minor skin infections
Victorian Community Pharmacist Statewide Pilot [2]	The Department of Health commenced a 12-month statewide pilot in October 2023 to test an expanded role for community pharmacists. During the pilot, participating and appropriately trained community pharmacists can provide certain Schedule 4 medications under a structured prescribing model for: - Treatment for shingles - Treatment for flare-up of mild plaque psoriasis - Resupply of select oral contraceptive pills without a prescription - Antibiotics for uncomplicated urinary tract infections
New South Wales Pharmacy Trial [3]	A trial for appropriately trained pharmacists to provide community access to important medications and treatments usually only available with a prescription, is running in NSW. - Supply certain treatments for uncomplicated urinary tract infections (UTIs) to women aged from 18 to 65 years (inclusive) who meet the eligibility criteria from May 2023 (due for completion May 2024). - Continue a prescription for the resupply of a low-risk oral contraceptive pill (the pill) for women aged from 18 to 35 years (inclusive) that meet the eligibility criteria from September 2023 (dues for completion September 2024).

[1] Ref: https://www.tewhatuora.govt.nz/assets/For-the-health-sector/Community-pharmacy/Minor-ailments-service/Community-Pharmacy-Minor-Ailments-Service-Summary.pdf
[2] Ref: https://www.health.vic.gov.au/primary-care/victorian-community-pharmacist-statewide-pilot
[3] Ref: https://www.health.nsw.gov.au/pharmaceutical/Pages/community-pharmacy-pilot.aspx